Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY

University Hospital Basel

Status and phase: Completed; Phase 1

Conditions: Taste Disorder, Primary, Sweet

Treatments: Other: mixed liquid meal; Dietary Supplement: lactisole

Study type: Interventional

Funder types: Other

Identifiers

NCT01304823

EKBB 69/04.03

Details and patient eligibility

About

The purpose of this study is to determine the functional significance of sweet taste receptors in the secretion of GI satiation peptides by using a specific sweet taste receptor antagonist to block sweet taste perception in the gastrointestinal tract.

Full description

There is strong evidence that taste signaling mechanisms identified in the oral epithelium also operate in the gut. It is suggested that open-type enteroendocrine cells directly sense nutrient via alpha-gustducin coupled taste receptors to modulate the secretion of glucagon like peptide-1 (GLP-1) and peptide YY (PYY). Several nutrient responsive G-protein coupled receptors have been identified in the human gut, including the sweet taste responsive T1R2/T1R3 heterodimer, the amino acid/umami responsive T1R1/T1R3 as well as GPR120 for unsaturated long-chain free fatty acids.The functional significance of sweet taste receptors in the secretion of GLP-1 and PYY will be determined by intraduodenal perfusion of glucose (I) or a mixed liquid meal (II) with or without lactisole (450 ppm) in a double blind, 5-way crossover trial including 10 healthy subjects.

Enrollment: 10 patients

Sex: Male

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy subjects
• BMI of 19.0-24.5
• Age 18-40
• stable body weight for at least 3 month

Exclusion criteria

• smoking
• substance abuse
• regular intake of medication
• medical or psychiatric illness
• gastrointestinal disorders or food allergies

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

10 participants in 5 patient groups, including a placebo group

glucose

Active Comparator group

Description:

intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)

Treatment:

Dietary Supplement: lactisole

glucose + lactisole

Active Comparator group

Description:

intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole

Treatment:

Dietary Supplement: lactisole

mixed liquid meal

Active Comparator group

Description:

intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)

Treatment:

Other: mixed liquid meal

mixed liquid meal + lactisole

Active Comparator group

Description:

intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole

Treatment:

Other: mixed liquid meal

saline + lactisole

Placebo Comparator group

Description:

saline (0.9 %; rate: 2.5 mL/min for 180 min) + 450 ppm lactisole

Treatment:

Dietary Supplement: lactisole